Abstract: Device for arterial puncture assistance. In an embodiment, the device comprises an upper component, lower component, and coupling mechanism that couples the lower component to the upper component. The upper component may comprise a platform configured to support a syringe. The lower component may comprise one or more finger holes, wherein each of the one or more finger holes is configured to receive a human finger therethrough, so as to enable contemporaneous stabilization of the lower component on the human finger and palpation of an arterial pulse by the human finger during an arterial puncture.

Abstract: This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, e.g., to treat disease caused by asthma and chronic inflammation, such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein can inhibit CD8 T cell-mediated cellular immune responses and can, for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines.

Abstract: Conjugates of synthetic nanocarriers, complexed with syngeneic (self) proteins adducted with haptens or other poorly immunogenic antigens (antigens of low immunogenicity), elicit selective humoral responses or antibodies against the hapten or antigen and not to self-protein. Compositions include these conjugates, which can be used as vaccines. Methods of making and using them are described herein. In a typical embodiment, a conjugate including a hapten or antigen of low immunogenicity associated with a particular disease (e.g., infection, cancer) can be used as a vaccine by eliciting antibodies that specifically neutralize the hapten or antigen. These hapten (and other poorly immunogenic antigen)-carrying nanocarriers selectively target antigen presenting cells resulting in a strong anti-hapten humoral response, and thus find use in vaccines for cancer (e.g., cancers of lung, cervix, breast, brain, liver pancreas, ovaries, skin, etc.

Abstract: A device to change the temperature of a localized volume of material. A workable device includes at least one heat transfer mechanism having an external surface for direct contact with an exposed surface of the material. A working fluid is directed by input and output conduits to contact an internal surface of the heat transfer mechanism. The heat transfer mechanism exchanges heat between the working fluid and the material. Temperature of the working fluid may be regulated by a thermal system disposed at a remote location. An optional temperature sensing element may monitor a local temperature of the heat transfer mechanism or otherwise infer a temperature of a portion of the material. Sometimes, a device includes a cooperating anchoring arrangement to facilitate holding the heat transfer mechanism in a desired spot. Certain devices may be plastically deformed to a desired device shape.

Abstract: The present invention provides a method of treating heart failure with reduced ejection fraction, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the anchoring of PP2A to mAKAP?. This composition is preferably in the form of a viral based gene therapy vector that encodes a fragment of mAKAP? to which PP2A binds.

Abstract: A device and method for preserving corneal graft tissue. In one embodiment, a device for preserving corneal graft tissue comprises: a first chamber; a second chamber; and a corneal graft tissue suspension assembly that is configured to retain and suspend the corneal graft tissue between the first chamber and the second chamber, the first chamber being fluidly isolated from the second chamber when the corneal graft tissue is graft tissue is retained and suspended within the corneal graft tissue suspension assembly. In one embodiment, a method includes filling a first chamber of a device with a first preservation medium and filling a second chamber of the device with a second preservation medium different than or the same as the first, a corneal graft tissue being located between the first and second chambers.

Abstract: In certain embodiments, enhancement of a vision of a user may be facilitated. In some embodiments, a visual test presentation including a set of stimuli may be provided to a user. Feedback related to the set of stimuli may be obtained during the visual test presentation. The feedback may be provided to a prediction model, and the prediction model may be configured based on the feedback. Subsequent to the configuring of the prediction model, live video stream data, eye characteristic information, or other information may be provided to the prediction model to obtain a set of modification parameters. A modified version of the live video stream data may be generated and displayed to the user based on the live video stream and the set of modification parameters.

Abstract: In some embodiments, initial feedback indicating threshold characteristics (under which a user sees initial stimuli presented on a user interface) may be provided to a prediction model, and a set of predicted characteristics (for a set of locations of the user interface) and a set of confidence scores associated with the set of locations may be obtained via the prediction model. Based on the set of confidence scores, one or more locations may be selected to be tested during a visual test presentation. As an example, the locations may be selected over one or more other locations of the set of locations based on the set of confidence scores. Based on predicted characteristics associated with the selected locations, stimuli may be presented at the selected locations during the visual test presentation. Visual defect information for the user may be generated based on feedback from the visual test presentation.

Abstract: Topical formulations of CoQ10 reduce the rate of tumor growth in an animcal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.

Abstract: A method is disclosed for improving accuracy of visual field testing in head-mounted displays. The method includes retrieving a visual field testing pattern for a head-mounted display, the visual field testing pattern including icons displayed at respective locations in a visual field of the head-mounted display. The visual field testing pattern is generated on the head-mounted display. Data is retrieved from a tilt sensor, located at the head-mounted display, for detecting degrees of head tilt of a user wearing the head-mounted display and the degree of head tilt is determined. A comparison is made between the degree of head tilt of the user to a first threshold degree. In response to the degree of head tilt of the user meeting or exceeding the first threshold degree, a recommendation to the user is generated for display on the head-mounted display.

Abstract: In certain embodiments, enhancement of a field of view of a user may be facilitated via one or more dynamic display portions. In some embodiments, one or more changes related to one or more eyes of a user may be monitored. Based on the monitoring, one or more positions of one or more transparent display portions of wearable device may be adjusted, where the transparent display portions enable the user to see through the wearable device. A live video stream representing an environment of the user may be obtained via the wearable device. A modified video stream derived from the live video stream may be displayed on one or more other display portions of the wearable device.

Abstract: Systems and methods for quantitatively imaging retinal blood vessel oxygen saturation using retinal auto-fluorescence (AF) are provided. One or more excitation sources can be used to provide light to the retina, and retinal AF can be detected by one or more detectors. The quantitative level of oxygen saturation in the blood can be determined based on the intensity of AF.

Abstract: Compositions specific for TNF-receptor superfamily member 25 (TNFRSF25, DR3) modulate the immune re-sponse by regulating T regulatory cells.

Abstract: In some embodiments, a set of eye images related to a subject may be provided to a prediction model. A first prediction may be obtained via the prediction model, where the first prediction is derived from a first eye image and indicates whether an eye condition is present in the subject. A second prediction may be obtained via the prediction model, where the second prediction is derived from a second eye image and indicates that the eye condition is present in the subject. An aspect associated with the first prediction may be adjusted via the prediction model based on the second prediction's indication that the eye condition is present in the subject. One or more predictions related to at least one eye condition for the subject may be obtained from the prediction model, where the prediction model generates the predictions based on the adjustment of the first prediction.

Abstract: The present invention provides a method of treating heart failure with reduced ejection fraction, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the anchoring of PP2A to mAKAP?. This composition is preferably in the form of a viral based gene therapy vector that encodes a fragment of mAKAP? to which PP2A binds.

Abstract: In some embodiments, a set of eye images related to a subject may be provided to a prediction model. A first prediction may be obtained via the prediction model, where the first prediction is derived from a first eye image and indicates whether an eye condition is present in the subject. A second prediction may be obtained via the prediction model, where the second prediction is derived from a second eye image and indicates that the eye condition is present in the subject. An aspect associated with the first prediction may be adjusted via the prediction model based on the second prediction's indication that the eye condition is present in the subject. One or more predictions related to at least one eye condition for the subject may be obtained from the prediction model, where the prediction model generates the predictions based on the adjustment of the first prediction.

Abstract: In certain embodiments, image data modifications may be facilitated for dynamic vision defects. In some embodiments, one or more eyes of a user may be monitored while a set of stimuli are displayed to the user. Feedback related to the set of stimuli may be obtained, where the feedback indicates (i) whether or how the user sees one or more stimuli of the set or (ii) one or more characteristics related to the eyes that occurred when such stimuli are displayed. A set of modification profiles associated with the user may be generated based on the feedback, where each modification profile of the set (i) is associated with eye-related characteristics and (ii) includes modification parameters to be applied to an image to modify the image for the user when eye-related characteristics of the user matches the associated eye-related characteristics.

Abstract: A general method of analyzing immune signaling networks for identification of potential therapeutic targets in complex, chronic medical disorders is described. The disclosure provides the CD3?/CD56+ natural killer (NK) cell population as a potential therapeutic target in the clinically-overlapping disorders Gulf War Illness (GWI) and Myalg Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The disclosure also provides a method for improving or restoring Natural Killer (NK) cell function by stimulating the NK cells with interleukin-15 (IL-15).

Abstract: Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin).